Business
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Genev
About this update from Addex Therapeutics Ltd
[{"type":"image","alt":"Addex Therapeutics","displaySize":"","headline":null,"caption":"Addex Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":231,"height":115,"url":"https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i1_J.LrQ5M.Eo1NBP2WLjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1f8146359a7fe2dec0ebef0293b159e7","width":231,"height":115}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Strong cash position of CHF2.8 million at end of Q1 2025","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models ","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Regained rights to our phase 2 mGlu2 PAM asset, ADX71149","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studies","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Entered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery","length":144,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":450,"olType":false},{"type":"text","content":"Ad Hoc Announcement Pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Geneva, Switzerland, June 19, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2025 financial results and provided a corporate update.","length":308,"tagName":"p"},{"type":"text","content":"“We have had a great start to 2025 both in terms of product development and achieving business milestones. Progress continues well and on track with our GABAB PAM drug candidate in chronic cough. Positive data from this program in multiple preclinical models was recently presented at the prestigious American cough conference. We have also regained rights to our Phase 2 mGlu2 PAM asset, ADX71149,” said Tim Dyer, CEO of Addex. “Solidifying our position to use mGlu5 NAMs in brain injury, we entered an option agr...